A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Jul 2017 Planned primary completion date changed from 28 Jun 2018 to 5 May 2021.
    • 23 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jul 2021.
    • 13 Jul 2015 Planned number of patients changed from 225 to 245, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top